Are Krishna Institu. latest results good or bad?

Krishna Institute of Medical Sciences (KIMS) reported its financial results for the quarter ended September 2025, revealing a complex operational landscape. The company achieved net sales of ₹960.70 crores, reflecting a year-on-year growth of 23.59% and a sequential increase of 10.22% compared to the previous quarter. This indicates a strong top-line performance amid challenging conditions. However, the net profit for the same quarter was ₹66.90 crores, which represents a significant year-on-year decline of 37.71% and a sequential decrease of 14.89% from the prior quarter. This marks the second consecutive quarter of declining profitability, raising concerns about the sustainability of the company's earnings. The operating margin, excluding other income, stood at 21.23%, down sharply from 28.06% in the same quarter last year, indicating a compression of operational efficiency. The profit after tax (PAT) margin also halved to 7.53% from 15.53% year-on-year, reflecting the operational challenges faced by the company during its expansion phase. KIMS' financial profile has been impacted by a significant increase in interest expenses, which more than doubled to ₹45.00 crores, and a 61.22% rise in depreciation expenses to ₹66.10 crores. This increase in costs has contributed to the erosion of net margins and raised questions about the company's aggressive expansion strategy, which is heavily reliant on debt financing. Despite these challenges, KIMS maintains a robust return on equity (ROE) of 20.26%, indicating strong underlying asset quality. The company's valuation metrics suggest that it is trading at elevated multiples, reflecting market expectations for a recovery in profitability as new capacities come online. Overall, KIMS' latest results highlight a strong revenue growth trajectory overshadowed by significant profitability pressures and operational challenges. The company has seen an adjustment in its evaluation, which reflects the current financial dynamics and the ongoing transition phase in its expansion strategy.